Edition:
United Kingdom

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

134.19USD
13 Sep 2019
Change (% chg)

$1.10 (+0.83%)
Prev Close
$133.09
Open
$132.00
Day's High
$136.59
Day's Low
$131.75
Volume
107,528
Avg. Vol
100,726
52-wk High
$179.00
52-wk Low
$105.19

Summary

Name Age Since Current Position

John Oyler

50 2010 Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

57 2018 General Manager, China and President

Howard Liang

55 2015 Chief Financial Officer and Chief Strategy Officer

Eric Hedrick

50 2019 Interim Chief Medical Officer, Immuno-Oncology

Jane Huang

45 2016 Chief Medical Officer, Hematology

Hing Ling Chau

44 2018 Company Secretary

Xiaodong Wang

55 2016 Non-Executive Director

Timothy Chen

61 2016 Non-Executive Independent Director

Donald Glazer

73 2013 Non-Executive Independent Director

Michael Goller

43 2015 Non-Executive Independent Director

Ranjeev Krishana

44 2014 Non-Executive Independent Director

Thomas Malley

50 2016 Non-Executive Independent Director

Jing-Shyh Su

66 2018 Non-Executive Independent Director

Qingqing Yi

46 2014 Non-Executive Independent Director

Biographies

Name Description

John Oyler

Mr. John Victor Oyler is Executive Chairman of the Board, Chief Executive Officer of the Company. He has served as a member of our Board since October 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1998 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was bought by The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated, an oncology-focused biopharmaceutical company listed on the Nasdaq under ticker symbol “GNTA”. Mr. Oyler began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from the Massachusetts Institute of Technology in June, 1990 and an MBA from Stanford University in January, 1996.

Xiaobin Wu

Dr. Xiaobin Wu is General Manager, China and President of the Company. He joined our Company in April 2018 as our General Manager, China and President. He has more than 25 years of experience in the pharmaceutical industry, including 17 years leading China operations of multinational companies, with expertise in research and development, strategy, commercialization and general management. Before joining the Company in April 2018, Dr. Wu served as the Country Manager of Pfizer China from 2009 to April 2018 and Regional President of Pfizer Essential Health in the Greater China Region from 2017 to April 2018. Under his leadership, Pfizer China experienced significant growth to become a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from 2004 to 2009. Before joining Wyeth, Dr. Wu served as the General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany. Dr. Wu has served as a Vice Chairman of the R&D Based Pharmaceutical Association Committee (RDPAC) in China since 2008. He also serves as Vice Chairman of the Pharmaceutical Chamber of Commerce of China’s National Association of Industry & Commerce, and Executive Vice Chairman of the Chinese Pharmaceutical Enterprise Association. He is also a research fellow at the Research Center of National Drug Policy and Ecosystem (NDPE) of China Pharmaceutical University in Nanjing, China.

Howard Liang

Mr. Howard Liang, Ph.D. is Chief Financial Officer and Chief Strategy Officer of the company since July 2015. Prior to joining us, from 2005 to 2015, Dr. Liang was at Leerink Partners LLC, a leading investment bank specializing in the healthcare industry, where he served as a Managing Director and Head of Biotechnology Equity Research. Dr. Liang served as a Senior Biotechnology Analyst at two full-service investment banks: A.G. Edwards Inc., from 2004 to 2005, and JMP Securities, from 2003 to 2004. From 2000 to 2003, Dr. Liang served as an Associate Analyst at Prudential Securities, where he covered major and specialty pharmaceuticals. Before Wall Street, from 1992 to 2000, Dr. Liang was with Abbott Laboratories, where he was a Senior Scientist and a member of one of the pharmaceutical industry’s leading structure-based discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including six in Nature, Science, and Proceedings of the National Academy of Sciences. Dr. Liang received his B.S. in Chemistry from Peking University in July, 1985, and both his MBA and Ph.D. in Biochemistry and Molecular Biology from the University of Chicago in June, 2001 and March, 1992 respectively.

Eric Hedrick

Dr. Eric E. Hedrick, M.D. is Interim Chief Medical Officer, Immuno-Oncology of the Company. He has served in different roles at the Company since June 2015 and currently holds the position of Chief Advisor. He was previously Chief Medical Officer at Epizyme, Vice President of Oncology Development and Interim Chief Medical Officer at Pharmacyclics, and Group Medical Director at Genentech. Prior to joining the industry, Dr. Hedrick was an Attending Physician on the Hematology Service at Memorial Sloan-Kettering Cancer Center. He has an M.D. from the University of Maryland School of Medicine.

Jane Huang

Dr. Jane Huang, M.D., is Chief Medical Officer, Hematology of the Company. Prior to joining us, Dr. Huang served as the Vice President, Clinical Development at Acerta Pharma from April 2015 to September 2016, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Previously, she worked at Genentech, Inc from 2005 to March 2015, serving most recently as Group Medical Director, where she played a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. She is also an Adjunct Clinical Assistant Professor in Oncology at Stanford University, specializing in Thoracic Oncology. Dr. Huang received her Bachelor of Science degree in Biological Sciences from Stanford University in June, 1998 and her M.D. from University of Washington School of Medicine in June, 1998. She is board certified in hematology, oncology, and internal medicine, and she completed her residency in Internal Medicine and fellowships in Hematology and Oncology at Stanford University.

Hing Ling Chau

Ms. Chau Hing Ling Anita is Company Secretary of the Company since May 17, 2018. She joined Vistra Corporate Services (HK) Limited in June 2013 and now serves as a director of Corporate Services, where she leads a team of professional staff to provide a full range of corporate services and listed company secretary services. Prior to joining Vistra Corporate Services (HK) Limited, she was an associate director of Corporate Secretarial of an international corporate services provider. Ms. Chau has over 15 years of experience in the corporate services industry. She is currently the company secretary of Keen Ocean International Holding Limited, a company listed on the GEM Board of the Stock Exchange (stock code: 8070), Rici Healthcare Holdings Limited, a company listed on the Main Board of the Stock Exchange (stock code: 1526), Persta Resources Inc., (stock code: 3395), a company listed on the Main Board of the Stock Exchange and Sheung Moon Holdings Limited, a company listed on the GEM Board of the Stock Exchange (stock code: 8523) and the joint company secretary of COFCO Meat Holdings Limited, a company listed on the Main Board of the Stock Exchange (stock code: 1610) and Guangdong Kanghua Healthcare Co., Ltd. a company listed on the Main Board of the Stock Exchange (stock code: 3689) respectively. Ms. Chau received a master of laws majoring in corporate and financial law from The University of Hong Kong in November 2007. She has been a fellow member of the Institute of Chartered Secretaries and Administrators and the Hong Kong Institute of Chartered Secretaries since May 2013.

Xiaodong Wang

Dr. Xiaodong Wang, Ph.D., is Non-Executive Director of the Company since February 2016. He has also served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his B.S. in Biology from Beijing Normal University in July, 1984 and his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center in May, 1991. Dr. Wang has been a member of the National Academy of Science, USA since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

Timothy Chen

Mr. Timothy Y. (Tim) Chen is Non-Executive Independent Director of the Company since February 2016. Since January 2018, Mr. Chen has served as the Chairman of Foxconn Industrial Internet Company, a company listed on the Shanghai Stock Exchange since June 2018. From January 2016 to March 2018, he served as the President and Chief Executive Officer of Asia Pacific Telecom and as the Corporate Vice President of Hon Hai Technology Group. He served as the President of Telstra International Group and Advisor to Telstra Chief Executive Officer from November 2012 to December 2015. He was also the Chairman of Autohome, a company listed on the Nasdaq and a director of Qingdao Haier Co., Ltd., a company listed on the Shanghai Stock Exchange. He was a Non-Executive Director on the Board of Telstra Corporation Limited, a company listed on the Australian Securities Exchange between April 2012 and November 2012. Previously, Mr. Chen was a partner of a China Opportunities Fund within GL Capital Group. He was the Chief Executive Officer of National Basketball Association China from 2007 to 2010; the Corporate Vice President of Microsoft and the Chief Executive Officer of its Greater China Region from 2003 to 2007; and the Corporate Vice President of Motorola and the Chairman and President of Motorola (China) Electronics from 2001 to 2003. Before Motorola, he was the Chief Executive Officer of 21CN Cybernet, a company listed on the Stock Exchange from 2000 to 2001. Prior to 2000, Mr. Chen spent eight years in China with Motorola, including serving as the General Manager responsible for the sales and marketing for the Greater China Cellular Infrastructure Division. He also spent nine years with AT&T Bell Laboratories in the United States. Mr. Chen earned an MBA Degree from the University of Chicago in August, 1991 and a Master’s Degree in both computer science and mathematics from Ohio State University in June, 1982.

Donald Glazer

Mr. Donald Wayne Glazer is Non-Executive Independent Director of the company since February 2013. Mr. Glazer has served as a member of the Board of Trustees of GMO Trust, a mutual fund group, since 2000 and as the Chairman of the Board of GMO Trust since 2005. Mr. Glazer was a Co-Founder and Secretary, and from 2002 until 2010, Vice Chairman, of Provant, Inc., a provider of performance improvement training solutions. From 1992 to 1995 Mr. Glazer was President of Mugar/Glazer Holdings and from 1992 to 1993 served as Vice Chairman—Finance of New England Television Corp and WHDH-TV, Inc. From 1997 to the present, Mr. Glazer has served as Advisory Counsel to Goodwin Procter LLP. From 1970 to 1978 Mr. Glazer was an associate and from 1978 to 1992 a partner at Ropes & Gray LLP, a Boston law firm. At Ropes & Gray, Mr. Glazer chaired the firm’s Emerging Companies Group. Mr. Glazer was also a Lecturer in Law at Harvard Law School from 1978 to 1991, teaching a course called The Business Lawyer. Mr. Glazer is a former member of the boards of directors of Environics Inc.; Kronos Incorporated; Reflective Technologies, Inc.; and Teleco Oilfield Services Inc. Mr. Glazer received his A.B. from Dartmouth College in June, 1966; J.D. from Harvard Law School in June, 1969, where he was an editor of the Harvard Law Review; and L.L.M. from the University of Pennsylvania Law School in May, 1970. Additionally, Mr. Glazer is a co-author of both Glazer and FitzGibbon on Legal Opinions, Third Edition (Aspen Publishers) and Massachusetts Corporation Law & Practice, Second Edition (Aspen Publishers).

Michael Goller

Mr. Michael J. Goller is Non-Executive Independent Director of the company since April 2015. Mr. Goller has been with Baker Bros. Advisors LP since 2005 and currently serves as a Partner. Prior to joining Baker Bros., Mr. Goller served as an Associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. Mr. Goller received a B.S. in Molecular and Cell Biology from The Pennsylvania State University in May, 1997 and Master’s degrees in each of Biotechnology (School of Engineered and Applied Sciences) and Business Administration (Wharton School) from the University of Pennsylvania in May, 2005. Mr. Goller has served as a director at DBV Technologies SA, a company listed on the Nasdaq and on Euronext Paris, since 2015.

Ranjeev Krishana

Mr. Ranjeev Krishana is Non-Executive Independent Director of the company since October 2014. Mr. Krishana has worked at Baker Bros. Advisors LP from 2011 to the present and currently serves as Head of International Investments. Prior to joining Baker Bros., Mr. Krishana held a series of commercial, strategy, and business development leadership roles for Pfizer, Inc.’s pharmaceutical business across a variety of international regions and markets, including Asia, Eastern Europe, and Latin America. Mr. Krishana was at Pfizer from 2003 to 2007 and from 2008 to 2011. From 2008 to 2010, Mr. Krishana was based in Beijing, China, where he served as a Senior Director and a member of the Pfizer China Leadership Team. Mr. Krishana began his career as a strategy consultant at Accenture plc. Mr. Krishana received a B.A. in Economics and Political Science from Brown University in May, 1995, and a Masters of Public Policy from Harvard University in June, 2011.

Thomas Malley

Mr. Thomas Robert (Tom) Malley is Non-Executive Independent Director of the Company since January 2016. Mr. Malley has served as a director of BeiGene Beijing since 2016. Mr. Malley has served as president of Mossrock Capital, LLC, a private investment firm, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley received a B.S. in Biology from Stanford University in January 1991. Mr. Malley has held directorships in the following listed companies: • Kura Oncology, Inc., a company listed on the Nasdaq, as a director since 2015; • Kiniksa Pharmaceuticals, a company listed on the Nasdaq, as a director since 2016; • OvaScience, Inc., a company listed on the Nasdaq, as a director from 2012 to 2017; • Synageva BioPharma Corp., a Company listed on the Nasdaq prior to its delisting in May 2015 in connection with the sale of the company, as a director from 2006 to 2015; • Puma Biotechnology, Inc., a company listed on the Nasdaq, as a director from 2011 to 2015; and • Cougar Biotechnology, Inc., a company listed on the Nasdaq prior to its delisting in July 2009 in connection with the sale of the company, as a director from 2007 to 2009.

Jing-Shyh Su

Mr. Jing-Shyh S. (Sam) Su is Non-Executive Independent Director of the company since April 2018. Mr. Su retired from Yum! Brands, Inc., a company listed on the New York Stock Exchange (“Yum! Brands”), in May 2016, where he served as Vice Chairman of the Board, and was the Chairman and CEO of the company’s China division. During Mr. Su’s 26 years with Yum! Brands, its China division grew from just four restaurants to over 7,000 to become the largest multinational restaurant chain in China, contributing more than half of Yum! Brands’ world-wide revenues in 2015. Mr. Su started his career with Yum! Brands in 1989 as KFC International’s director of marketing for the North Pacific region. In 1993, he became vice president of North Asia for both KFC and Pizza Hut. Mr. Su was named president of Greater China for Tricon Global Restaurants International upon Pepsi’s spin-off of the restaurant business in 1997. Before joining Yum! Brands, Mr. Su worked with Procter & Gamble in Germany and Taiwan. Mr. Su earned his undergraduate degree at the National Taiwan University in June, 1974, an M.Sc. degree in Chemical Engineering at Pennsylvania State University in May, 1978, and an MBA at the Wharton School of the University of Pennsylvania in May, 1983. Mr. Su currently serves as a director of Li Ning Company Limited, a company listed on the Main Board of the Stock Exchange (stock code: 2331), and of Peet’s Coffee China.

Qingqing Yi

Mr. Qingqing Yi is Non-Executive Independent Director of the company since October 2014. Mr. Yi is a Partner at Hillhouse Capital. He has worked with Hillhouse since the inception of the firm in 2005. Prior to joining Hillhouse, Mr. Yi was an Equity Research Analyst at China International Capital Corporation. Mr. Yi’s work at Hillhouse includes investments in the healthcare and consumer sectors in both its public and private equity portfolios. Mr. Yi received a B.S. degree in Engineering from Shanghai Maritime University in July, 1995 and an MBA from University of Southern California in May, 2003.

Basic Compensation